CCAR1 5′ UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance

Cell Research

Volumn 26, Issue 6, 2016, Pages 655-673

  Li, Gaopeng ^a   Wu, Xiaoli ^a   Qian, Wenchang ^a,b   Cai, Huayong ^a   Sun, Xinbao ^a   Zhang, Weijie ^a,b   Tan, Sheng ^a,b   Wu, Zhengsheng ^c   Qian, Pengxu ^d   Ding, Keshuo ^c   Lu, Xuefei ^a,b   Zhang, Xiao ^a   Yan, Hong ^c   Song, Haifeng ^e   Guang, Shouhong ^a,b   Wu, Qingfa ^a,b   Lobie, Peter E ^f   Shan, Ge ^a,b   Zhu, Tao ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CCAR1 5 UTR; miR 1254; miRancer; tamoxifen

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; ARGONAUTE PROTEIN; CCAR1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; EIF2C2 PROTEIN, HUMAN; MICRORNA; MIRN1254 MICRORNA, HUMAN; TAMOXIFEN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; BIOLOGICAL MODEL; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; RNA STABILITY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; APOPTOSIS REGULATORY PROTEINS; ARGONAUTE PROTEINS; BASE SEQUENCE; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; RNA STABILITY; TAMOXIFEN;

EID: 84973369534     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2016.32     Document Type: Article

References (61)

1. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014; 9:287-314.
2. Brummer A, Hausser J. MicroRNA binding sites in the coding region of mRNAs: extending the repertoire of post-transcriptional gene regulation. Bioessays 2014; 36:617-626.
3. Sharp PA. The centrality of RNA. Cell 2009; 136:577-580.
4. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 2012; 13:271-282.
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-233.
6. Pesole G, Mignone F, Gissi C, Grillo G, Licciulli F, Liuni S. Structural and functional features of eukaryotic mRNA untranslated regions. Gene 2001; 276:73-81.
7. Shimakami T, Yamane D, Jangra RK, et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci USA 2012; 109:941-946.
8. Liu M, Roth A, Yu M, et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev 2013; 27:2543-2548.
9. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5' UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30:460-471.
10. Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol 2008; 630:206-219.
11. Viedma-Rodriguez R, Baiza-Gutman L, Salamanca-Gomez F, et al. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer. Oncol Rep 2014; 32:3-15.
12. Loo LW, Wang Y, Flynn EM, et al. Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat 2011; 127:297-308.
13. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014; 42:D68-73.
14. Kim JH, Yang CK, Heo K, Roeder RG, An W, Stallcup MR. CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol Cell 2008; 31:510-519.
15. Rishi AK, Zhang L, Yu Y, et al. Cell cycle-and apoptosis-regulatory protein-1 is involved in apoptosis signaling by epidermal growth factor receptor. J Biol Chem 2006; 281:13188-13198.
16. Down TA, Hubbard TJ. Computational detection and location of transcription start sites in mammalian genomic DNA. Genome Res 2002; 12:458-461.
17. Chien CH, Sun YM, Chang WC, et al. Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data. Nucleic Acids Res 2011; 39:9345-9356.
18. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4:721-726.
19. Wu X, Brewer G. The regulation of mRNA stability in mammalian cells: 2.0. Gene 2012; 500:10-21.
20. Kruger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res 2006; 34:W451-W454.
21. Mathews DH, Disney MD, Childs JL, Schroeder SJ, Zuker M, Turner DH. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci USA 2004; 101:7287-7292.
22. Farazi TA, ten Hoeve JJ, Brown M, et al. Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol 2014; 15:R9.
23. Kong X, Li G, Yuan Y, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One 2012; 7:e41523.
24. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-256.
25. Hiscox S, Jiang WG, Obermeier K, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of ?-catenin phosphorylation. Int J Cancer 2006; 118:290-301.
26. Raffo D, Berardi DE, Pontiggia O, Todaro L, de Kier Joffe EB, Simian M. Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Res Treat 2013; 142:537-548.
27. Jiang Y, Zhao X, Xiao Q, et al. Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition. J Mol Cell Biol 2014; 6:352-354.
28. Jin K, Kong X, Shah T, et al. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci USA 2012; 109:2736-2741.
29. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA. org resource: targets and expression. Nucleic Acids Res 2008; 36:D149-D153.
30. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20.
31. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57.
32. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25:25-29.
33. Huang B, Warner M, Gustafsson JA. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol 2014; 418 Pt 3:240-244.
34. Garcia-Becerra R, Santos N, Diaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2012; 14:108-145.
35. Scherbakov AM, Andreeva OE, Shatskaya VA, Krasil'nikov MA. The relationships between snail1 and estrogen receptor signaling in breast cancer cells. J Cell Biochem 2012; 113:2147-2155.
36. Hardy KM, Booth BW, Hendrix MJ, Salomon DS, Strizzi L. ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2010; 15:191-199.
37. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83.
38. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Competing and noncompeting activities of miR-122 and the 5 exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci USA 2013; 110:1881-1886.
39. Winter J, Diederichs S. Argonaute proteins regulate microRNA stability: Increased microRNA abundance by Argonaute proteins is due to microRNA stabilization. RNA Biol 2011; 8:1149-1157.
40. Chatterjee S, Grosshans H. Active turnover modulates mature microRNA activity in Caenorhabditis elegans. Nature 2009; 461:546-549.
41. Brown JA, Bulkley D, Wang J, et al. Structural insights into the stabilization of MALAT1 noncoding RNA by a bipartite triple helix. Nat Struct Mol Biol 2014; 21:633-640.
42. Wilusz JE, JnBaptiste CK, Lu LY, Kuhn CD, Joshua-Tor L, Sharp PA. A triple helix stabilizes the 3? ends of long noncoding RNAs that lack poly(A) tails. Genes Dev 2012; 26:2392-2407.
43. Jackson RJ. Cytoplasmic regulation of mRNA function: the importance of the 3? untranslated region. Cell 1993; 74:9-14.
44. Kuersten S, Goodwin EB. The power of the 3? UTR: translational control and development. Nat Rev Genet 2003; 4:626-637.
45. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505:344-352.
46. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell 2012; 149:515-524.
47. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144:1032-1044.
48. Bocker W. [The WHO classification of breast tumours and tumours of the female genital organs: pathology and genetics.] Verh Dtsch Ges Pathol 2002; 86:116-119.
49. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403-410.
50. Willmarth NE, Albertson DG, Ethier SP. Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells. Breast Cancer Res 2004; 6:R531-539.
51. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; 8:R59.
52. Giordano C, Catalano S, Panza S, et al. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene 2011; 30:4129-4140.
53. Kuo PL, Hsu YL, Cho CY. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 2006; 5:3209-3221.
54. Ortega-Cava CF, Raja SM, Laiq Z, et al. Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer. J Carcinog 2011; 10:29.
55. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA 2004; 101:15166-15171.
56. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11:1487-1495.
57. Orom UA, Lund AH. Isolation of microRNA targets using biotinylated synthetic microRNAs. Methods 2007; 43:162-165.
58. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell 2011; 44:667-678.
59. Leinonen R, Sugawara H, Shumway M, International Nucleotide Sequence Database Collaboration. The sequence read archive. Nucleic Acids Res 2011; 39:D19-D21.
60. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10:R25.
61. Corcoran DL, Georgiev S, Mukherjee N, et al. PARalyzer: definition of RNA binding sites from PAR-CLIP short-read sequence data. Genome Biol 2011; 12:R79.